Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from COSMO Pharmaceuticals N.V. ( (CH:COPN) ).
Cosmo Pharmaceuticals N.V. will publish its 2025 full-year financial results on 9 March 2026 at 07:00 a.m. CET and will host a live conference call and audio webcast at 10:00 a.m. CET the same day for investors, analysts and journalists. Chief Executive Officer Giovanni Di Napoli and Chief Financial Officer Svetlana Sigalova will present the company’s recent financial and operational performance, outline strategic initiatives, growth opportunities and outlook, and take questions during a Q&A session, with the webcast and presentation to remain accessible online for three months. The company will simultaneously release its 2025 annual report and ESG report on its website, and has flagged key upcoming investor-relations dates on its financial calendar, underscoring its ongoing engagement with the capital markets and broader stakeholder community.
The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF136.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.
More about COSMO Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V. is a life-science company focused on MedTech AI, dermatology, gastrointestinal diseases and contract development and manufacturing (CDMO). It designs, develops and manufactures advanced medical solutions aimed at meeting critical healthcare needs and improving standards of care, serving leading global pharmaceutical and MedTech partners. Founded in 1997 and headquartered in Dublin with subsidiaries in the US and Italy, Cosmo positions itself at the intersection of science and technology to support patients and healthcare professionals worldwide.
Average Trading Volume: 56,489
Technical Sentiment Signal: Buy
Current Market Cap: CHF1.94B
See more insights into COPN stock on TipRanks’ Stock Analysis page.